Marta Santamariña

Marta Santamariña

Auto-generated profile, based on publicly available information

Marta Santamariña

Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LSLenka Stolarova
Lenka Stolarova
PKPetra Kleiblova
Petra Kleiblova
PZPetra Zemankova
Petra Zemankova
BŠBarbora Šťastná
Barbora Šťastná
MJMarketa Janatova
Marketa Janatova
ZKZdenek Kleibl
Zdenek Kleibl
Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense CHEK2 variants of uncertain significance (VUS) have been identified, hampering the clinical utility of germline genetic testing (GGT). Experimental Design: We collected 460 CHEK2 missense VUS identified by the ENIGMA consortium in 15 countries. Their functional characterization was performed using CHEK2-complementation assays quantifying KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1–CHEK2-knockout cells. Concordant results in both functional assays were used to categorize CHEK2 VUS from 12 ENIGMA case–control datasets, including 73,048 female patients with breast cancer and 88,658 ethnicity-matched controls. Results: A total of 430/460 VUS were successfully analyzed, of which 340 (79.1%) were concordant in both functional assays and categorized as functionally impaired (N = 102), functionally intermediate (N = 12), or functionally wild-type (WT)–like (N = 226). We then examined their association with breast cancer risk in the case–control analysis. The OR and 95% CI (confidence intervals) for carriers of functionally impaired, intermediate, and WT-like variants were 2.83 (95% CI, 2.35–3.41), 1.57 (95% CI, 1.41–1.75), and 1.19 (95% CI, 1.08–1.31), respectively. The meta-analysis of population-specific datasets showed similar results. Conclusions: We determined the functional consequences for the majority of CHEK2 missense VUS found in patients with breast cancer (3,660/4,436; 82.5%). Carriers of functionally impaired missense variants accounted for 0.5% of patients with breast cancer and were associated with a moderate risk similar to that of truncating CHEK2 variants. In contrast, 2.2% of all patients with breast cancer carried functionally wild-type/intermediate missense variants with no clinically relevant breast cancer risk in heterozygous carriers.

1 December 1995 in Journal of Helminthology
Verified
Journal Article
Closed access
Raúl IglesiasRaúl Iglesias
Raúl Iglesias
JLJosé M. Leiro-Vidal
José M. Leiro-Vidal
FUF.M. Ubeira
F.M. Ubeira
MSM.T. Santamarina
M.T. Santamarina
MSM.L. Sanmartín
M.L. Sanmartín
To investigate antigenic differences between the developmental stages ofAnisakis simplex, somatic, excretion–secretion and detergent-solubilized surface antigen preparations of third- and fourth-stageA. simplexlarvae, and a somatic antigen preparation of adults, were characterized by SDS–PAGE and immunoblotting using mouse immune serum containing antibodies against the two larval stages. Excretion–secretion and surface antigen preparations from thirdstage larvae behaved very differently from those of fourth-stage larvae, in both SDS-PAGE and immunoblotting; this suggests that certain excretion–secretion and surface antigens are highly stage-specific. By contrast, somatic components of third- and fourth-stage larvae were found to have very similar banding patterns, suggesting conservation of these components during the development of the parasite in mice. The SDS-PAGE and immunoblotting results for adult somatic components seem to support this hypothesis

1 March 1994 in Journal of Fish Diseases
Verified
Journal Article
Closed access
PDF file
JTJ. L. Tojo
J. L. Tojo
MSM. T. Santamarina
M. T. Santamarina
JLJosé M. Leiro-Vidal
José M. Leiro-Vidal
FUF. M. Ubeira
F. M. Ubeira
MSM. L. Sanmartin
M. L. Sanmartin

13 November 2012 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
LFLaura Fachal
Laura Fachal
MSM. Santamariña
M. Santamariña
ABA. Blanco
A. Blanco
ÁCÁngel Carracedo
Ángel Carracedo
Ana V EgaAna V Ega
Ana V Ega

1 June 2001 in Journal of Parasitology
Verified
Journal Article
Closed access
RVR. Vilas
R. Vilas
EPE. Paniagua
E. Paniagua
MSM. L. Sanmartín
M. L. Sanmartín
MSM. T. Santamarina
M. T. Santamarina
FUF. M. Ubeira
F. M. Ubeira
Electrophoretic analyses of phosphoglucomutase (PGM) and fumarase (FH) in a population of Lecithochirium rufoviride parasitizing Conger conger, revealed 2 independent activity zones for each enzyme on starch gel electrophoresis. However, some individuals exhibited only 1 activity zone for 1 or both enzymes. The banding patterns observed strongly suggest that (1) PGM is coded by 2 polymorphic loci, Pgm-1 (expressed in all individuals) with allelic frequencies not significantly different from those expected under Hardy-Weinberg equilibrium, and Pgm-2 (expressed in a subset of individuals); and (2) FH is coded by 2 loci, Fh-2 (monomorphic and expressed in all individuals) and Fh-1 (expressed in a subset of individuals). A high degree of concordance (88.75%) was observed between the expression and nonexpression of Pgm-2 and Fh-1. The most likely explanations for these findings are either variation in enzyme expression with developmental stage or the presence of null alleles at high frequencies in the population.

15 August 2023
Verified
Other
Open access
LSLenka Stolarova
Lenka Stolarova
PKPetra Kleiblova
Petra Kleiblova
PZPetra Zemankova
Petra Zemankova
BŠBarbora Šťastná
Barbora Šťastná
MJMarketa Janatova
Marketa Janatova
ZKZdenek Kleibl
Zdenek Kleibl
Characteristics of 12 case-control datasets from the ENIGMA consortium partners.